Unknown

Dataset Information

0

Randomized, single blind, controlled trial to evaluate the prime-boost strategy for pneumococcal vaccination in renal transplant recipients.


ABSTRACT:

Unlabelled

Renal transplant recipients are at increased risk of developing invasive pneumococcal diseases but may have poor response to the 23-valent pneumococcal polysaccharide vaccine (PPV). It may be possible to enhance immunogenicity by priming with 7-valent pneumococcal conjugate vaccine (7vPnC) and boosting with PPV 1 year later. In a randomized single-blind, controlled study, adult recipients of renal transplants received either 7nPVC or PPV followed by PPV 1 year later. The vaccine response was defined as 2-fold increase in antibody concentration from baseline and an absolute post-vaccination values ?1 µg/ml. The primary endpoint was vaccine response of the primed group (7vPnC/PPV) compared with single PPV vaccination. Antibody concentrations for 10 serotypes were measured at baseline, 8 weeks after first vaccination, before second vaccination, and 8 weeks after second vaccination. Of 320 screened patients, 80 patients were randomized and 62 completed the study. Revaccination with PPV achieved no significant increase of immune response in the 7vPnC/PPV group compared with the single PPV recipients A response to at least 1 serotype was seen in 77.1% of patients who received 7vPnC and 93.1% of patients who received PPV (P = 0.046). After second vaccination response to at least 1 serotype was seen in 87.5% patients of 7vPnC/PPV group and 87.1% patients of PPV group (non significant p). The median number of serotypes eliciting a response was 3.5 (95% CI 2.5-4.5) in the 7vPnC/PPV group versus 5 (95% CI 3.9-6.1) in the PPV group (non-significant p). Immunogenicity of pneumococcal vaccination was not enhanced by the prime-boost strategy compared with vaccination with PPV alone. Administration of a single dose of PPV should continue to be the standard of care for adult recipients of renal transplants.

Trial registration

EudraCT 2007-004590-25.

SUBMITTER: Tobudic S 

PROVIDER: S-EPMC3460962 | biostudies-literature | 2012

REPOSITORIES: biostudies-literature

altmetric image

Publications

Randomized, single blind, controlled trial to evaluate the prime-boost strategy for pneumococcal vaccination in renal transplant recipients.

Tobudic Selma S   Plunger Veronika V   Sunder-Plassmann Gere G   Riegersperger Markus M   Burgmann Heinz H  

PloS one 20120928 9


<h4>Unlabelled</h4>Renal transplant recipients are at increased risk of developing invasive pneumococcal diseases but may have poor response to the 23-valent pneumococcal polysaccharide vaccine (PPV). It may be possible to enhance immunogenicity by priming with 7-valent pneumococcal conjugate vaccine (7vPnC) and boosting with PPV 1 year later. In a randomized single-blind, controlled study, adult recipients of renal transplants received either 7nPVC or PPV followed by PPV 1 year later. The vacci  ...[more]

Similar Datasets

| S-EPMC8279581 | biostudies-literature
| S-EPMC9323946 | biostudies-literature
| S-EPMC7036218 | biostudies-literature
| S-EPMC10058820 | biostudies-literature
| S-EPMC6471676 | biostudies-literature
2019-02-19 | E-MTAB-7697 | biostudies-arrayexpress
| S-EPMC3760864 | biostudies-literature
| S-EPMC3749006 | biostudies-literature
| S-EPMC11309389 | biostudies-literature
| S-EPMC8115940 | biostudies-literature